[Antibiotics: the race continues].
Heike
H
Oberpichler-Schwenk
D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000187:drug effects; D024901:Drug Resistance, Multiple, Bacterial; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy; D000077732:Fidaxomicin; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D000097583:Ceftaroline
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077732:Fidaxomicin; D000097583:Ceftaroline